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ABSTRACT Seven-transmembrane (G-protein cou-
pled) receptors are key regulators of normal physiology
and a large number of diseases, and this family of
receptors is the target for almost half of all drugs. Cell
culture models suggest that homodimerization and
heterodimerization of 7-transmembrane receptors reg-
ulate processes including specificity of ligand binding
and activation of downstream signaling pathways, mak-
ing receptor dimerization a critical determinant of
receptor biology and a promising new therapeutic
target. To monitor receptor dimerization in cell-based
assays and living animals, we developed a protein
fragment complementation assay based on firefly lucif-
erase to investigate dimerization of chemokine recep-
tors CXCR4 and CXCR7, two 7-transmembrane recep-
tors with central functions in normal development,
cancer, and other diseases. Treatment with chemokine
ligands and pharmacologic agents produced time- and
dose-dependent changes in reporter signal. Chemo-
kines regulated reporter bioluminescence for CXCR4
or CXCR7 homodimers without affecting signals from
receptor heterodimers. In a tumor xenograft model of
breast cancer, we used bioluminescence imaging to mea-
sure changes in receptor homodimerization in response
to pharmacologic agents. This technology should be valu-
able for analyzing function and therapeutic modulation of
receptor dimerization in intact cells and living mice.—
Luker, K. E., Gupta, M., Luker, G. D. Imaging chemokine
receptor dimerization with firefly luciferase complemen-
tation. FASEB J. 23, 823–834 (2009)
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Recent studies suggest that multiple types of trans-
membrane receptors exist as homodimeric or het-
erodimeric complexes, rather than monomers. In par-
ticular, receptor dimerization is emerging as a key
paradigm for seven-transmembrane (7-TM) receptors
(also known as G-protein-coupled receptors), the fam-
ily of receptors targeted most commonly by clinically
approved pharmaceutical agents. Formation of recep-
tor homodimers and heterodimers has been implicated
in essentially all aspects of the biology of 7-TM recep-
tors, including intracellular trafficking, ligand binding,
pharmacologic inhibition, signal transduction, and in-
ternalization (1). However, homodimerization and het-
erodimerization of 7-TM receptors and the conse-
quences of blocking these complexes remain poorly
understand and controversial (2), and very little is
known about dynamics of receptor interactions in a
living animal.
Beyond the relevance for receptor biochemistry and
signaling, complexes of 7-TM receptors also represent
promising new therapeutic targets to modulate func-
tions of these molecules in vivo. One relevant example
is CXCR4, a 7-TM chemokine receptor with key func-
tions in normal physiology and diseases including can-
cer, rheumatoid arthritis, and HIV (3). Blocking ho-
modimerization of CXCR4 with a synthetic peptide
interrupts downstream signaling pathways and chemo-
taxis, suggesting a novel approach to inhibit CXCR4
that likely can be applied to other 7-TM receptors (4).
To translate this treatment strategy from cell culture
assays to animal models and ultimately patients, it will
be essential to develop noninvasive imaging assays to
quantify changes in receptor dimerization in vivo.
Dimerization of 7-TM receptors has been analyzed
with a variety of experimental techniques, including
coimmunoprecipitation and resonance energy transfer
methods based on fluorescence or bioluminescence
(FRET and BRET, respectively). FRET and BRET tech-
niques have the advantage of monitoring receptor
complexes in intact cells, allowing effects of biological
ligands and pharmacologic agents on receptor confor-
mations to be quantified in real time. Although a
limited number of studies have imaged BRET in living
mice, autofluorescence may limit detection of green
fluorescent protein (GFP) emission from BRET, and
the technique has not been used to monitor receptor
complexes in vivo (5). Therefore, no imaging reporter
system presently exists that can detect dimerization of
7-TM receptors and responses of these complexes to
physiological signals or pharmacologic intervention.
To image dynamics of receptor dimers in cell-based
assays and living mice, we used a protein fragment
complementation assay (PCA) based on firefly lucif-
erase (6). This system was used to analyze homodimers
and heterodimers of chemokine receptors CXCR4 and
CXCR7. CXCR7 recently has been characterized as a
receptor for chemokines CXCL11 and CXCL12, the
latter being the cognate ligand for CXCR4 (7). Similar
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to CXCR4, CXCR7 promotes growth of several differ-
ent types of cancer in mouse xenografts models, iden-
tifying CXCR7 as a potential new diagnostic and ther-
apeutic target in breast, prostate, lung, and other
cancers (8, 9). Using the firefly luciferase PCA, we were
able to monitor magnitude and kinetics of conforma-
tional changes in CXCR4 and CXCR7 dimers in cell-
based assays following treatment with physiological
ligands or small molecules targeted to each receptor.
The reporter system also allowed changes in receptor
complexes to be detected and quantified in an ortho-
topic xenograft model of breast cancer. These results
provide new insights into dynamics of CXCR4 and
CXCR7 dimerization and establish an imaging reporter
strategy to validate and optimize therapeutic agents
targeted to receptor complexes.
MATERIALS AND METHODS
DNA constructs
Luciferase complementation plasmids in vector pEF for
NLuc-416 and CLuc-398 were provided by Alnawaz Rehem-
tulla (University of Michigan, Ann Arbor, MI, USA). Mamma-
lian expression and lentiviral vector constructs for human
CXCR4 fused to NLuc-416 in plasmids pEF and FUGW,
respectively, were described previously (10). To generate
CXCR4-CLuc, we used polymerase chain reaction (PCR) to
amplify CXCR4 and fuse it to CLuc 398 in pEF (10). Human
CXCR7 was amplified by reverse transcriptase-PCR from
human breast cancer cell line MCF-7 and inserted into the
pEF, replacing CXCR4 in the NLuc and CLuc constructs.
Human 2-adrenergic receptor (plasmid template provided by
Roger Sunahara, University of Michigan, Ann Arbor, MI, USA)
was amplified by PCR and inserted into pEF to produce 2-AR-
NLuc-416. For all fusion proteins, the amino acid linker se-
quence was AAAQISYASRGGGSSGGG. All PCR products were
verified by DNA sequencing. Sequences of PCR primers are
provided in Supplemental Table 1.
Lentiviral vectors for these reporter constructs were pre-
pared in vectors FUGW or FUPW (10, 11). CXCR4 and
CXCR7 fusion proteins were digested with BglII and XbaI and
inserted into the blunted PacI site of FUGW (NLuc con-
structs) or FUPW (CLuc constructs). Complementation re-
porters were expressed from a human EF-1 promoter.
Mouse CXCL12- was amplified by PCR from the SDF-
degrakine plasmid (gift of Lishan Su, University of North
Carolina, Chapel Hill, NC, USA) and inserted into the BamHI
and EcoRI sites of pUB6/V5-HisA (Invitrogen, Carlsbad, CA,
USA). The ubiquitin promoter and CXCL12 were removed
with BglII and EcoRI and inserted into the blunted PacI site of
FUGW to create FUGW-CXCL12.
Cells
Human embryonic kidney 293 cells stably expressing large T
antigen from SV40 virus (293T) were from Open Biosystems
(Huntsville, AL, USA), and human breast cancer cell line
MDA-MB-231 and mouse NIH 3T3 cells were purchased from
the American Type Culture Collection (ATCC; Manassas, VA,
USA). All cells were cultured in Dulbecco modified Eagle
medium (DMEM; Invitrogen), 10% fetal bovine serum, 1%
glutamine, and 0.1% penicillin/streptomycin/gentamicin.
Cells were maintained in a 37°C incubator with 5% CO2.
To generate stable cell lines coexpressing various combi-
nations of CXCR4-NLuc, CXCR4-CLuc, CXCR7-NLuc, and
CXCR7-CLuc homodimers and heterodimers, we prepared
recombinant lentiviruses expressing each of these proteins as
described previously (11, 12). The 293T or 231 cells first were
transduced with supernatants containing CXCR4-NLuc or
CXCR7-CLuc in FUGW. Transduction efficiency was 100% as
determined by fluorescence microscopy. These cells then
were transduced with supernatants for CXCR4-CLuc or
CXCR7-CLuc in FUPW. Again, transduction efficiency for
CLuc constructs was 100%, as determined by fluorescence
microscopy for mPlum. Batch populations of transduced cells
were used for all experiments. 3T3 cells were transduced with
FUGW-CXCL12 or FUGW as a control were generated in the
same manner.
Live cell imaging
For transient transfections, 293T cells were transfected in
6-well plates with 3.5 g of each reporter plasmid and 0.25 g
of plasmid for Gaussia luciferase (Promega Corp, Madison,
WI, USA). In competition experiments, cells also were co-
transfected with an equal amount of unfused CXCR4 or
CXCR7 or FUGW vector control. One day after transfection,
cells were plated into 96-well plates at a density of 1  104
cells/well using a Multidrop 384 dispensing system (Lab-
systems, Thermo Fisher Scientific, Waltham, MA, USA), and
experiments were performed the subsequent day. Gaussia
luciferase activity was measured in a parallel set of quadrupli-
cate wells for each transfection condition and used to nor-
malize firefly luciferase reporter signals. Stably transduced
cell lines were plated in 96-well plates in the same manner
and used for experiments 1 day later. Immediately before
each assay, cells were switched to DMEM containing 0.2%
bovine serum albumin (Probumin; BD Biosciences, San Jose,
CA, USA). Quadruplicate samples were used for all experi-
mental conditions. Cells were treated with various concentra-
tions of CXCL11, CXCL12 (R&D Systems Inc, Minneapolis,
MN, USA), AMD3100 (Sigma-Aldrich, St. Louis, MO, USA),
TF14013 (gift of Nobutaka Fujii, Kyoto University, Kyoto,
Japan), CCX733, or CCX754 (gifts of ChemoCentryx Inc,
Mountain View, CA, USA), as described in figure legends. For
selected experiments, cells were treated with 0.4 M sucrose in
DMEM with 0.2% BSA or 50 M chloroquine (reagents from
Sigma). Incubation times for each agent are listed in figure
legends.
Bioluminescence imaging of live cells was performed on a
cryogenically cooled camera system (IVIS 100; Caliper Life
Sciences, Mountain View, CA, USA) as described previously
(6), using 0.5- to 5-min acquisition times, high sensitivity, and
field of view B. After imaging, total protein per well was
assayed by sulforhodamine B staining as described previously
(13). Bioluminescence imaging data were normalized to total
protein, and data were expressed as fold increase relative to
untreated controls in each experiment.
Western blots
Membrane preparations from stably transduced cell lines
were prepared as described previously (14). Lysates were
probed with 1:500 dilutions of antibodies to firefly luciferase
(Promega). Primary antibodies were detected with a 1:2000
dilution of secondary anti-goat antibody conjugated with
horseradish peroxidase. Blots were developed with enhanced
chemiluminescence (ECL) reagent (Amersham Biosciences
Corp., Piscataway, NJ, USA).
ELISA
CXCL12 levels in supernatants of 3T3-CXCL12 and 3T3-GFP
cells after 4 h of incubation were quantified by ELISA
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according to the manufacturer’s directions (Quantikine;
R&D Systems).
In vivo bioluminescence imaging
All animal procedures were approved by the University of
Michigan Committee for use and care of animals. Type 231
cells stably expressing CXCR4-NLuc and CXCR4-CLuc or
CXCR7-NLuc and CXCR7-CLuc were injected bilaterally into
the fourth inguinal mammary fat pads of 6- to 8-wk-old female
nude mice (Taconic, Hudson, NY, USA) (2106 breast
cancer cells/fat pad) as described previously (12). Cells were
coimplanted with 1 106 3T3 cells stably expressing CXCL12
and GFP or GFP alone. To regulate receptor dimerization,
mice were injected intraperitoneally with 5 mg/kg AMD310
or subcutaneously with 100 mg/kg CCX754 or matched
vehicle control. Imaging was performed at times before and
after injection, as listed in figure legends.
Bioluminescence imaging was performed on an IVIS Spec-
trum system (Caliper) as described previously (15). Images
were obtained for 5 min on high sensitivity and FOV C.
Imaging data were quantified as photon flux using Living
Image software (Caliper). Data for each tumor were normal-
ized to photon flux prior to treatment to account for differ-
ences in tumor sizes in various mice.
Statistics
Data for photon flux or fold induction of bioluminescence
were plotted as mean values with se. Pairs of data were
analyzed by two-tailed paired t test to determine statistically
significant differences (P0.05) (GraphPad Prism; Graph-
Pad, San Diego, CA, USA).
RESULTS
Firefly luciferase PCA for monitoring complexes
of CXCR4 and CXCR7
We previously have developed a PCA based on N- and
C-terminal fragments of firefly luciferase (NLuc and
CLuc, respectively) that have minimal background as-
sociation and high reconstitution of bioluminescence
when brought together by interacting proteins (6). To
develop an imaging assay for receptor dimerization, we
fused the intracellular C termini of CXCR4 or CXCR7
to either NLuc or CLuc, respectively. Changes in con-
formation of chemokine receptors in homodimeric or
heterodimeric complexes will alter the efficiency of
luciferase complementation, providing a quantitative
measurement of receptor dynamics (Fig. 1A). Chemo-
kine receptors remain functional when fused to lucif-
erase fragments (10), so the reporter molecules will
allow imaging of receptor complexes during physiolog-
ical signaling.
As an initial test of the assay system, we transiently
transfected 293T cells with pairs of NLuc and CLuc fusion
receptors so that cells coexpressed CXCR4 and CXCR7
homodimers or both orientations of CXCR4 and CXCR7
heterodimers. To determine specificity of receptor inter-
actions, we cotransfected cells with CXCR4- or CXCR7-
CLuc fusion proteins and 2-adrenergic receptor-NLuc.
2-Adrenergic receptor is a well-characterized 7-TM re-
ceptor with no known interactions with either CXCR4 or
CXCR7. We also transfected cells with each fusion protein
alone to control for bioluminescence from individual
luciferase fragments.
Figure 1. Firefly luciferase protein fragment complementation reporter for chemokine receptor dimers. A) Schematic diagram
of PCA. NLuc and CLuc fragments fused to intracellular C termini of chemokine receptors associate to produce light under
basal conditions. Chemokine ligands or small molecules alter association of luciferase fragments, depicted as conformational
changes in receptor pairs, changing the bioluminescent signal for cell-based and in vivo imaging. B) Type 293T cells were
transiently transfected with indicated complementation plasmids, cultured in medium with 10% serum, and assayed 48 h after
transfection. Reporter bioluminescence was quantified in intact cells using a CCD-camera device and normalized to Gaussia
luciferase activity as a transfection control (n4/condition).
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Under baseline conditions, bioluminescence was de-
tected readily from all combinations of CXCR4 and
CXCR7 homodimers and heterodimers. Reporter signal
was greatest from CXCR4 homodimers, with lesser
amounts produced by CXCR7 homodimers and both
NLuc and CLuc combinations of CXCR4 and CXCR7
heterodimers (Fig. 1B). The heterodimer pair of CXCR4-
NLuc/CXCR7-CLuc produced significantly greater biolu-
minescence than the reverse orientation of CXCR4-
CLuc/CXCR7-NLuc (P0.05). Previous BRET studies
reported that reciprocal changes in reporter proteins
from one 7-TM receptor to another altered the magni-
tude of signal produced by heterodimers, indicating that
BRET primarily detects changes in conformation between
preformed receptor complexes (16). Similarly, differ-
ences in bioluminescence produced by reciprocal combi-
nations of CXCR4 and CXCR7 fusion proteins suggest the
firefly luciferase PCA also reports changes in conforma-
tion between receptors. Our data are consistent with prior
research showing constitutive CXCR4 homodimers and
CXCR4-CXCR7 heterodimers (4, 17–19), and the results
indicate that CXCR7 also exists as homodimers. All com-
binations of CXCR4 and CXCR7 complexes had10-fold
more bioluminescence than heterodimeric complexes
formed with 2-adrenergic receptor-NLuc, showing spec-
ificity of the PCA for detecting chemokine receptor
complexes. Cells transfected with single NLuc or CLuc
constructs had no detectable bioluminescence, verifying
the requirement for both luciferase fragments to recon-
stitute enzyme activity (data not shown).
Ligand- and time-dependent changes in firefly
luciferase PCA
Previous studies report conflicting data for ligand-
dependent regulation of CXCR4 homodimers (16, 17,
19), and effects of chemokine ligands on CXCR7
homodimers have not been investigated. Chemokine
CXCL11 binds to CXCR7, while CXCL12 binds to both
CXCR4 and CXCR7 (7, 20). Having established feasi-
bility of the assay technique, we generated stable pop-
ulations of 293T cells for further biochemical analysis
in cell-based assays. Cell surface expression of CXCR4
and CXCR7 reporter constructs was verified by flow
cytometry (data not shown).
We treated stable 293T CXCR4 or CXCR7 ho-
modimer reporter cells with increasing concentrations
of CXCL12 and quantified bioluminescence immedi-
ately after adding chemokine. CXCL12 produced im-
mediate dose-dependent effects on reporter biolumi-
nescence for both CXCR4 and CXCR7 homodimers,
although the direction of change differed for each
chemokine receptor pair (Fig. 2). For CXCR4, incuba-
tion with CXCL12 decreased the magnitude of lucif-
erase activity relative to untreated cells. Incubation with
10 ng/ml CXCL12 significantly reduced biolumines-
cence from CXCR4 homodimerization (P0.05), and
1000 ng/ml decreased reporter activity by 30%. By
comparison, CXCL12 increased bioluminescence from
CXCR7 homodimers with significant effects at 100
ng/ml (P0.05) and a peak increase of 50% at 1000
ng/ml chemokine. These data show immediate re-
sponses of the homodimerization PCA to chemokine
ligands. Opposite responses of CXCR4 and CXCR7
homodimers to either decrease or increase biolumines-
cence, respectively, suggest that chemokines elicit dis-
tinct conformational changes in these receptors.
To further investigate responses of CXCR4 and CXCR7
homodimers to chemokines, we quantified changes in
reporter bioluminescence following extended incubation
with CXCL11 or CXCL12. We incubated stable 293T
reporter cells with various concentrations of CXCL11 or
CXCL12 for up to 4 h. For CXCR4, extended incubation
with CXCL12 decreased complementation signals by up
to 60% (Fig. 3A). The magnitude of this effect in-
creased over time through 2 h and reached steady state
levels for each concentration of chemokine, suggesting
that prolonged exposure to ligand increases the extent
of conformational changes in homodimeric complexes
and/or affects more receptors. Treatment with
CXCL11 did not alter bioluminescence from the
CXCR4 homodimer reporter (Fig. 3D), showing a
specific effect of CXCL12 on CXCR4 receptor com-
plexes.
Prolonged incubation with chemokines CXCL11 or
CXCL12 also produced time- and dose-dependent
changes in bioluminescence from CXCR7 homodimers
(Fig. 3B, C). CXCL12 elicited relatively greater effects
than CXCL11 on conformational changes and biolumi-
nescence, with 5- and 3.5-fold induction over un-
Figure 2. Immediate effects of chemokine ligands on CXCR4
and CXCR7 homodimers. Type 293T cells expressing firefly
luciferase PCA reporters for CXCR4 (A) or CXCR7 (B)
homodimers were treated with increasing concentrations of
CXCL12, and bioluminescence was quantified immediately
after adding chemokine. Data were normalized to biolumi-
nescence in control cells not incubated with CXCL12.
Graphed values are means 	 se (n4) representative of 2
independent experiments.
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treated control cells, respectively, at 1000 ng/ml. For
CXCL11, changes in reporter bioluminescence from
CXCR7 homodimerization peaked at 2 h, then re-
mained steady or declined minimally, while incubation
with 300 or 1000 ng/ml CXCL12 continued to increase
luciferase activity through at least 4 h. These data
demonstrate that changes in PCA signal (increase or
decrease) are not determined solely by efficacy of
chemokines but also are affected by relative differences
in positions of luciferase fragments within the receptor
dimer, similar to BRET or FRET (16).
We also investigated regulation of CXCR4 and
CXCR7 heterodimers by incubating 293T reporter cells
with increasing concentrations of CXCL11 or CXCL12
for 4 h. Neither CXCL11 nor CXCL12 altered the
magnitude of reporter bioluminescence from het-
erodimers, regardless of positions of NLuc or CLuc
fusions to CXCR4 or CXCR7 (Fig. 3D, E). No changes
in bioluminescence were evident at shorter incubation
times (immediate through 2 h), excluding the possibil-
ity that effects of chemokines were transient (data not
shown). Therefore, CXCR4 and CXCR7 form het-
erodimers that are not regulated by ligands for either
receptor. These results are consistent with a previous
study showing no effect of CXCL12 on coimmunopre-
cipitation of CXCR4 with CXCR7 (18).
To further validate specificity of the assay, we per-
formed competition experiments by cotransfecting
293T cells with equal amounts of CXCR4 or CXCR7
homodimer reporters and unfused CXCR4 or CXCR7.
Forty-eight hours after transfection, cells were treated
with 100 ng/ml CXCL12 for 2 h prior to assaying
reporter bioluminescence. For the CXCR4 homodimer
PCA, unfused CXCR4 or CXCR7 produced comparable
(25%) increases in luciferase activity under baseline
conditions as compared with vector control (P0.05)
(Fig. 4A). The increase in reporter signal caused by
unfused competitors is consistent these receptor mole-
cules altering basal conformation of CXCR4 ho-
modimers, producing the opposite response to incuba-
tion with chemokine ligand. Treatment with CXCL12
reduced bioluminescence from CXCR4 homodimeriza-
tion proportionately for cells without or with added
receptors lacking a luciferase fragment. In cells trans-
fected with the CXCR7 homodimerization PCA, un-
fused CXCR4 and CXCR7 reduced baseline biolumi-
nescence by 30 and 60%, respectively (P0.05 and
P0.01) (Fig. 4B). Incubation with CXCL12 produced
comparable increases in luciferase activity from CXCR7
homodimerization while maintaining the same relative
differences in bioluminescence observed under basal
conditions. Collectively, these data confirm specificity
of the PCA imaging assay and indicate that CXCR7 is a
more effective competitor for CXCR4 in homodimeric
complexes than CXCR4 is for CXCR7 homodimers.
CXCR4 and CXCR7 dimerization reporters function
in breast cancer cells
CXCR4 and CXCR7 promote growth of several differ-
ent types of cancer cells, including breast, lung, and
prostate, in mouse models of cancer (8, 9, 12, 21, 22).
To demonstrate that the dimerization PCA functions in
other cell types and establish a system for in vivo studies,
we used human breast cancer cell line MDA-MB-231, a
common model for primary and metastatic breast can-
cer. We generated stable cell lines expressing CXCR4
or CXCR7 homodimerization reporters or both combi-
nations of CXCR4 and CXCR7 heterodimer reporters.
These reporter cell lines show comparable responses to
chemokines as 293T dimerization reporter cells (Fig. 5
Figure 3. Time and dose-dependent ef-
fects of chemokine ligands. A–C) Type
293T cells stably expressing firefly lucif-
erase reporters for CXCR4 homodimers
(A) or CXCR7 homodimers (B, C) were
treated with increasing concentrations
of indicated chemokine ligand through
4 h. Reporter activity in intact cells was
quantified at various times, and data
were normalized to bioluminescence at
t  0 in untreated cells. Data are
means 	 se. D, E) Type 293T cells
expressing CXCR4 and CXCR7 homodimer and heterodimer reporters were treated for 4 h with increasing concentrations of
CXCL11 (D) or CXCL12 (E) before quantifying luciferase activity in living cells (n4/condition). Data were normalized to values
at t  0 for untreated cells; values are means 	 se. Presented results are representative of 2 or more independent experiments.
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and data not shown). These data show that the dimer-
ization PCA has comparable responses in more than
one cell type, indicating that this reporter technology
can be used generally to analyze chemokine receptor
complexes in a variety of different models.
We used these cells to test reversibility of signal from
the dimerization PCA following incubation with a che-
mokine ligand. We incubated 231 CXCR4 homodimer-
ization cells with increasing concentrations of CXCL12
for 15 min, washed the cells to remove the ligand, and
then measured bioluminescence after 30 min of incu-
bation in chemokine-free medium (Fig. 6). Treatment
with CXCL12 produced the expected dose-dependent
decrease in luciferase activity from CXCR4 homodimers.
Cells treated with either 10 or 100 ng/ml CXCL12 before
removal of the chemokine recovered luciferase activity
within 30 min to levels that slightly exceeded baseline
bioluminescence, while signal reversal was more modest
in cells treated with 1000 ng/ml CXCL12. Recovery of
CXCR4 homodimerization signal to levels slightly
greater than baseline is consistent with our prior work
showing that treatment with low-to-modest levels of
CXCL12 enhances subsequent signaling, potentially by
recruiting new receptors to the cell surface (10, 23).
These results establish reversibility of the dimerization
PCA, particularly following stimulation with lower con-
centrations of chemokine ligand.
Regulation of conformational changes in CXCR4 and
CXCR7 homodimers
In response to ligand binding, most 7-TM receptors
internalize via clathrin-coated pits and then enter ei-
ther recycling endosomes or acidified late endosomal
and lysosomal compartments (24). While chemokines
produce immediate changes in luciferase activity from
CXCR4 and CXCR7 homodimers, our data show that
the magnitude of change in bioluminescence increases
over time. These results suggest that conformational
changes in receptor complexes may be regulated by
receptor trafficking after ligand binding.
To investigate effects of selected steps in receptor
trafficking on CXCR4 and CXCR7 homodimerization, we
first performed experiments using hypertonic sucrose,
which blocks clathrin-coated endocytosis (25). Stable
MDA-MB-231 cell lines expressing either CXCR4 or
CXCR7 homodimerization reporters were pretreated
with 0.4 M sucrose for 30 min and then incubated with
increasing concentrations of CXCL12 for 2 h. For
Figure 5. CXCR4 and CXCR7 homodimerization reporters in
human breast cancer cells. MDA-MB-231 human breast can-
cer cells stably transduced with CXCR4 (A) or CXCR7 (B)
homodimerization reporters were treated with increasing
concentrations of CXCL12 for 4 h prior to assaying luciferase
activity (n4/condition, representative of 2 independent
experiments). Data were normalized to luciferase activity in
control cells not treated with CXCL12. Graphed values are
means 	 se. Insets show images of 96-well plates used for
plotted data.
Figure 4. Competition with unfused receptors. Type 293T
cells were transfected with equal amounts of plasmids for
CXCR4 (A) or CXCR7 PCA homodimers (B) and unfused
CXCR4 or CXCR7 or vector control. At 48 h after transfec-
tion, cells were treated for 2 h with increasing concentrations
of CXCL12 before quantifying bioluminescence. Data were
normalized to bioluminescence in cells transfected with vec-
tor control; values are means 	 se (n4). Results are
representative of 2 independent experiments.
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CXCR4, treatment with hypertonic sucrose significantly
enhanced the effect of CXCL12 to reduce biolumines-
cence (P0.05) (Fig. 7A). Incubation with 1000 ng/ml
CXCL12 reduced luciferase activity by 60% relative to
untreated cells, while addition of sucrose to the incuba-
tion medium decreased the reporter signal by 80%. By
comparison, hypertonic sucrose blocked the increase in
bioluminescence produced by prolonged incubation of
CXCR7 homodimers with CXCL12 (P0.05 at 1000 ng/
ml) (Fig. 7B). These data imply that conformational
changes in CXCR4 homodimers are reduced by clathrin-
dependent endocytosis, while conformational changes in
CXCR7 homodimers are promoted by this pathway.
We also analyzed functions of late endosomes and
lysosomes on receptor complexes, using chloroquine
or ammonium chloride to inhibit acidification of these
compartments. Type 231 reporter cells were treated
with low or high concentrations of CXCL12 for 2 h in
the presence or absence of these pharmacologic agents.
Neither chloroquine nor ammonium chloride altered
the reduction in CXCR4 homodimerization reporter
activity in response to CXCL12 (Fig. 7C). However,
acidified intracellular compartments were necessary for
CXCL12 to elicit conformational changes in CXCR7
homodimers during extended periods of incubation
(Fig. 7D). Treatment with chloroquine or ammonium
chloride almost completely abrogated effects of CXCL12
to increase luciferase activity from CXCR7 homodimers
(P0.05). Together with results using hypertonic sucrose,
these data show that internalization and trafficking
through acidified intracellular compartments promote
conformational changes in CXCR7, but not CXCR4,
homodimers.
Effects of specific inhibitors on receptor complexes
To further investigate the firefly luciferase PCA for mon-
itoring conformational changes in receptor complexes,
we used compounds that selectively block binding of
CXCL12 to CXCR4 (AMD3100, TF14013) or CXCL11
and CXCL12 binding to CXCR7 (CCX733, CCX754) (7,
26, 27). We incubated 293T reporter cells with increasing
concentrations of inhibitor alone for 30 min and then
treated cells with a modest concentration of chemokine
(100 ng/ml) for 2 h before quantifying bioluminescence.
For CXCR4 homodimers, CXCL12 alone produced the
expected decrease in reporter signal, and this effect was
blocked by both CXCR4 inhibitors (Fig. 8A, B). Our EC50
values of 10 and 30 nM for TF14013 and AMD3100,
respectively, are comparable to those reported from a
BRET study of CXCR4 homodimerization (16). Treat-
ment with 10 nM AMD3100 modestly activated the
CXCR4 reporter without and with CXCL12. Potentially,
this effect may be due to partial agonist effects of
AMD3100 in some experimental systems, although such
effects typically are seen at higher concentrations of
compound (28). While BRET has shown opposite effects
of CXCL12 and inverse agonists structurally related to
TF14013 on CXCR4 homodimerization (16), TF14013
alone did not alter bioluminescence for CXCR4 comple-
mentation. However, the highest concentration of
TF14013 combined with CXCL12 increased reporter sig-
nal above that for CXCR4 homodimers alone (P0.05),
suggesting allosteric regulation of ligand-regulated con-
formational changes in CXCR4 homodimerization (29).
CXCL12-dependent reductions in CXCR4 homodimer-
ization signal were not affected significantly by either
CXCR7 inhibitor, although higher concentrations of
CCX754 and to a lesser extent CCX733 produced modest
increases in bioluminescence (Fig. 8C, D).
None of the tested inhibitors blocked CXCL11- or
CXCL12-dependent increases in bioluminescence from
CXCR7 homodimerization reporters. However, treat-
ment with CXCR7 inhibitors alone enhanced peak
reporter activity for CXCR7 homodimerization by
2.5- and 3.5-fold for CCX754 and CCX733, respec-
tively, and significant increases (P0.05) first were
detected at 100 and 10 nM, respectively (Fig. 8E, F).
Therefore, while these agents block binding of
CXCL11 and CXCL12 to CXCR7, the compounds
function like chemokine ligands with respect to CXCR7
homodimerization. We also observed that treatment
with 1 M of either CXCR4 inhibitor increased biolu-
minescence for CXCR7 homodimerization, indicating
a loss of receptor selectivity at concentrations substan-
tially above the EC50 (Fig. 8G, H). None of the tested
compounds altered reporter bioluminescence for
CXCR4-CXCR7 heterodimers (data not shown). Over-
all, these data establish that pharmacologic regulation
of receptor complexes can be quantified in living cells
with the firefly luciferase PCA.
Imaging receptor complexes in vivo
We used an orthotopic xenograft model of breast
cancer to investigate the PCA for imaging complexes of
CXCR4 and CXCR7 in vivo. We implanted mice with
231 cells stably expressing CXCR4 and CXCR7 ho-
modimer reporters or CXCR4-CXCR7 heterodimers.
For experiments with CXCR4 homodimers and het-
Figure 6. Reversal of chemokine-dependent conformational
changes in CXCR4 homodimers. Type 231 cells stably ex-
pressing CXCR4 homodimer reporters were treated for 15
min with various concentrations of CXCL12 before quantify-
ing bioluminescence (no washout). Parallel wells of cells were
treated identically with CXCL12, washed with PBS, and then
incubated for 30 min without chemokine (30 min washout).
Data were normalized to bioluminescence in control cells not
treated with chemokine (NT) and graphed as means 	 se
(n4/condition, representative of two independent experi-
ments).
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erodimers of CXCR4 and CXCR7, we also coimplanted
murine fibroblasts stably expressing CXCL12 to repro-
duce secretion of this chemokine by stromal cells in the
microenvironment of human breast cancer and stimu-
late conformational changes in CXCR4 complexes (30)
(Supplemental Fig. 1).
In cultured cells, extended incubation with CXCL12
reduced bioluminescence from the CXCR4 homodimer
reporter, and the effect of CXCL12 on receptor com-
plexes was inhibited by AMD3100. We hypothesized that
CXCL12-producing fibroblasts in the tumor microenvi-
ronment would elicit a similar reduction in CXCR4 ho-
modimer signal that could be increased by treating mice
with AMD3100. As evidence supporting this model, we
first tested the hypothesis in cell-based assays. We treated
231 CXCR4 homodimer PCA cells with CXCL12 and then
added AMD3100 to medium containing this chemokine.
Cells incubated with CXCL12 alone showed the expected
reduction in bioluminescence from the CXCR4 ho-
modimerization reporter (Fig. 9A). By comparison, treat-
ment for 4 h with AMD3100 produced dose-dependent
increases in luciferase activity (P0.01), showing that
AMD3100 can reverse conformational changes elicited by
CXCL12.
To extend this model to animal studies, we ob-
tained baseline bioluminescence images of mice im-
planted with tumor xenografts of CXCR4 ho-
modimer or CXCR4-CXCR7 heterodimer reporter
cells. Mice then were treated with a single dose of
AMD3100 and imaged to quantify effects on dimer-
ization. Four hours after administering AMD3100,
bioluminescence from CXCR4 homodimers in-
creased by 2.5-fold above pretreatment levels
(P0.01) (Fig. 9B, C). Bioluminescence from CXCR4
homodimer tumors subsequently decreased by 30 h.
By comparison, AMD3100 had no effect on biolumi-
nescence from CXCR4-CXCR7 heterodimers at ei-
ther time point, showing specificity for CXCR4 ho-
modimers. These data demonstrate that the CXCR4
homodimerization PCA can quantify in vivo inhibition of
CXCL12-mediated conformational changes in receptor
complexes.
To investigate pharmacologic regulation of CXCR7
complexes in vivo, we used the CXCR7-specific com-
pound CCX754. In cell-based assays, treatment with this
compound significantly increased CXCR7 homodimer-
ization in 231 reporter cells (Fig. 10A). We implanted a
separate cohort of mouse 231 CXCR7 or CXCR4 ho-
modimer reporter cells. Because cell culture studies
revealed that CCX754 increased luciferase complemen-
tation, we coimplanted these tumors with fibroblasts
transduced only with GFP. We imaged tumor-bearing
Figure 7. Effects of endocytosis and acidified intracellular compartments on conformational changes. Type 231 CXCR4 (A, C)
or CXCR7 (B, D) homodimer reporter cells were pretreated with medium containing 0.4 M sucrose or medium alone (A, B) for
30 min prior to 2 h of incubation with CXCL12 added to the pretreatment medium. Cells in panels C and D were incubated
with CXCL12 in medium containing 50 M chloroquine or vehicle control for 2 h before quantifying bioluminescence. Data
were normalized to luciferase activity in cells not treated with CXCL12; graphed values are means 	 se (n4/condition,
representative of two independent experiments).
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mice before and after treatment with the CXCR7
modulator CCX754. Bioluminescence from CXCR7
homodimerization increased significantly by 1 h after
treatment and returned to baseline levels the following
day, demonstrating in vivo regulation of CXCR7 com-
plexes (Fig. 10B, C). Treatment with CCX754 did not
alter bioluminescence from CXCR4 homodimers, and
neither CXCR4 nor CXCR7 reporter signals were af-
fected by treatment with vehicle control. Collectively,
these data establish the firefly luciferase PCA for mon-
itoring specific pharmacologic regulation of chemo-
kine receptor complexes in living animals.
DISCUSSION
Previous studies have used resonance energy transfer
techniques (FRET, BRET) and coimmunoprecipitation
to analyze 7-TM receptor complexes in living cells.
These studies suggest that receptor dimers are the
functional units of 7-TM receptors with heterodimeric
complexes modifying ligand binding, allosteric regula-
tion of receptors, and activation of downstream signal-
ing pathways. These cell culture studies indicate that
dynamics of receptor homodimerization and het-
erodimerization are critical for normal and pathologi-
cal functions of 7-TM receptors and point to receptor
complexes as promising new targets for therapy. To
bridge the gap between cell culture studies, in vivo
physiology, and treatment, it is essential to develop
quantitative assays for receptor dimerization in living
animals.
We developed a firefly luciferase PCA to image dimeric
complexes of chemokine receptors in intact cells and
living mice. Using this system, we demonstrated constitu-
tive association of CXCR4 and CXCR7 as homodimers
and heterodimers. These data validate previous studies
showing constitutive homodimerization of CXCR4 and
heterodimerization of CXCR4 and CXCR7, and we dem-
onstrate for the first time that CXCR7 also exists as
preformed dimers (4, 17–19, 31). Chemokine ligands
altered conformations of CXCR4 and CXCR7 ho-
modimers, respectively, but neither CXCL11 nor
CXCL12 affected reporter signals from heterodimeric
complexes. CXCR4-CXCR7 heterodimers have been re-
ported to alter CXCR4 signaling in cultured cells (18, 32),
Figure 8. Pharmacologic modulation of
chemokine receptor dimerization. Sta-
bly transduced CXCR4 homodimer
(A–D) or CXCR7 homodimer (E–H)
reporter cells were incubated with vehi-
cle control or increasing concentrations
of CXCR4 inhibitor (AMD3100, TF14013)
or CXCR7 inhibitor (CCX733, CCX754)
for 2 h; 100 ng/ml CXCL12 (A–H),
CXCL11 (E–H), or vehicle control then
was added to cells for an additional 2 h
in continued presence of inhibitor.
Bioluminescence was quantified in liv-
ing cells (n4/condition). Data were normalized to control cells untreated with either inhibitor or chemokine and
expressed as fold increase relative to control. Symbols represent means 	 se. Data are representative of two
independent experiments.
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suggesting that fundamental differences in interactions
between CXCR4 homodimers and CXCR4-CXCR7 het-
erodimers control outputs of downstream effector mole-
cules. The firefly luciferase PCA provides a new method to
link dynamics of receptor complexes to effects on signal-
ing pathways in cell culture and animal models.
Our results also establish that this imaging reporter can
be used to quantify pharmacologic modulation of chemo-
kine receptor dimerization in cells and mice. We moni-
tored effects of CXCR4 inhibitors to block binding of
CXCL12 to the receptor and indirectly regulate CXCR4
homodimerization. We also determined that two preclin-
ical inhibitors of CXCR7 directly produce changes in
homodimerization of CXCR7, in addition to previously
validated inhibition of chemokine binding to this recep-
tor (7). Our data suggest effects of these compounds to
block tumor growth in animal models may be mediated in
part by altering conformations of CXCR7 complexes,
potentially controlling ligand binding or coupling to
intracellular effectors.
Previous studies have used resonance energy transfer
techniques (FRET or BRET) to investigate conforma-
tional changes in CXCR4 homodimers or complexes of
CXCR4 with other 7-TM receptors in cell-based assays (4,
16, 17, 33). Results obtained with both techniques indi-
cate that CXCR4 exists as preformed homo- and het-
erodimeric complexes, including a heterodimeric com-
plex with CXCR7 (18). FRET techniques typically show
modest changes in signal (30%) from conformational
changes in CXCR4 following treatment with CXCL12.
BRET assays of CXCR4 complexes typically show larger
changes in signal in response to CXCL12 (2- to 3-fold),
likely due to enzymatic amplification of energy transfer
from Renilla luciferase to the acceptor fluorescent pro-
tein. FRET and BRET studies of CXCR4 homodimers
typically have quantified changes in signal intensity after
5–10 min of incubation with CXCL12 or pharmacologic
agent and have not analyzed effects of extended treat-
ment with chemokine. Interestingly, a BRET study by
Babcock et al. (19) analyzed signal changes following 1 h
of incubation with CXCL12, but these authors found only
minimal effects of ligand on CXCR4 complexes.
The firefly luciferase PCA described in this manuscript
produces changes in reporter signals that are comparable
to those reported for early changes in CXCR4 complexes
measured with FRET or BRET techniques. Our data for
immediate responses of CXCR4 and CXCR7 ho-
modimeric complexes were obtained using 1–2 min of
image acquisition, which is shorter than typically de-
scribed for FRET and BRET experiments. The firefly
luciferase PCA shows that conformational changes in
CXCR4 and CXCR7 homodimeric complexes are ampli-
fied over time. For CXCR7 homodimers, progressive
changes in bioluminescence require clathrin-dependent
endocytosis and acidified intracellular compartments.
These data suggest that conformational changes in
CXCR7 homodimers continue to occur as this receptor
traffics to lysosomes, an organelle where a large fraction
of intracellular CXCR7 resides (34). It is unclear why
Babcock et al. (19) found only minimal changes in
Figure 9. In vivo imaging of CXCR4 receptor dimers.
A) Type 231 cells stably transduced with CXCR4 dimeriza-
tion reporters were incubated in cell culture with 1 g/ml
CXCL12 for 15 min. AMD3100 or vehicle control then was
added to CXCL12-containing medium for 4 h before quan-
tifying bioluminescence in living cells (n4/condition).
Data are presented as mean 	 se bioluminescence relative
to values measured in cells not treated with CXCL12 or
AMD3100 (representative of 2 independent experiments).
B, C) Type 231 CXCR4 homodimer or CXCR4-CXCR7
heterodimer cells were coimplanted with CXCL12-produc-
ing fibroblasts into mammary fat pads of nude mice. B) Representative bioluminescence images of the same mouse prior
to treatment with 7.5 mg/kg AMD3100 i.p. and then 4 and 30 h later. CXCR4 homodimer tumors are on the right side of
the mouse; CXCR4-CXCR7 heterodimers are on the left. Bioluminescence is shown as a pseudocolor scale, with red the
highest and blue the lowest levels of photons. C) Quantified data from in vivo imaging experiments for CXCR4 and
CXCR4-CXCR7 tumors (n4/tumor type). **P  0.01.
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CXCR4 complexes after 1 h, while we found that chemo-
kine-dependent changes in CXCR4 homodimers increase
over time. We note that immediate conformational
changes in CXCR4 homodimers produced by our current
system had greater variation than with prolonged incuba-
tion times. We currently are testing alternative linkers to
improve the system as we use firefly luciferase PCA to
further investigate molecular regulation of CXCR4 and
CXCR7 complexes and effects of intracellular trafficking
on conformational changes in dimers. Notably, this PCA
allows us to move readily between cell-based and animal
models as we pursue these studies.
CXCR4 is a key regulator of many different disease
processes, including cancer, HIV, atherosclerosis, and
rheumatoid arthritis, and CXCR7 also has been impli-
cated in tumor progression and metastasis. Because of
the central role of these receptors in disease, develop-
ment of pharmacologic agents to inhibit or activate
these receptors is an active area of investigation for
many pharmaceutical companies and academic labora-
tories. The propensity of chemokine and other 7-TM
receptors to heterodimerize adds previously under-
appreciated complexity to targeting these molecules
therapeutically. Moreover, pharmacologic agents di-
rectly targeting receptor dimers, rather than ligand-
receptor binding, provide a promising new approach to
regulate 7-TM receptors (35). Taken together, our
studies show the utility of the PCA reporter for identi-
fying new therapeutic agents targeted to chemokine
receptor complexes and validating efficacy of these
agents in vivo. Moreover, we expect this general imag-
ing strategy can be implemented to quantify dimeriza-
tion of other 7-TM receptors and different families of
transmembrane receptors.
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